{"entity":{"id":"nct07788222","kind":"trial","name":"Sacituzumab Govitecan and Q901 in Advanced TNBC","aka":[],"tldr":"A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Yonsei University, not yet recruiting.","summary":"Sacituzumab Govitecan and Q901 in Advanced TNBC. ClinicalTrials.gov record last updated 2026-08-26: not yet recruiting. Enrollment is planned at 48 participants. Primary completion is estimated at 2028-05-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab govitecan and Q901. Registered primary measures: Objective Response Rate, ORR by RECIST v1.1.","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07788222","url":"https://clinicaltrials.gov/study/NCT07788222"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","tnbc-metastatic"],"sections":[],"technologies":["adc"],"targets":["trop2"],"drugs":["sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-08-26: not yet recruiting. Enrollment is planned at 48 participants. Primary completion is estimated at 2028-05-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT07788222","phase":"2","setting":"Sacituzumab Govitecan and Q901 in Advanced TNBC","sponsor":"Yonsei University","participation":[{"nct":"NCT07788222","source":"https://clinicaltrials.gov/study/NCT07788222","fetchedAt":"2026-10-07T16:56:51.027Z","studySha256":"72810f83c5eeca5d59280166340600af4d0935d9d774f722af0a6c1a02204b57","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-08-26","leadSponsor":"Yonsei University","collaboratorCount":0,"minimumAge":"19 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":48,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2026-09-01","startedType":"estimated","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07788222/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}